<h4>Introduction</h4>Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are effective agents for type 2 diabetes (T2D) management, yet interindividual variability in response mechanisms remains unclear. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.